Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: Canine studies

Clinical Cancer Research

Volumn 2, Issue 4, 1996, Pages 721-734

  Khanna, Chand ^a   Hasz, Diane E ^b   Klausner, Jeffrey S ^a   Anderson, Peter M ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; LIPOSOME; RECOMBINANT INTERLEUKIN 2;

AEROSOL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG TOXICITY; EOSINOPHIL; FEMALE; INHALATIONAL DRUG ADMINISTRATION; LUNG LAVAGE; LYMPHOCYTE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL;

AEROSOLS; ANIMALS; ANTIGENS, CD11; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; DOGS; DRUG CARRIERS; FEMALE; INTERLEUKIN-2; LIPOSOMES; LYMPHOCYTE ACTIVATION; NEOPLASMS, EXPERIMENTAL;

EID: 0029912238     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. American Cancer Society. Cancer Facts and Figures: 1994. Atlanta, GA: American Cancer Society.
2. Potter, D. A., Glenn, S., Kinsella, T., Gladstein, E., Lack, E. E., Restrepo, C., White, D. E., Seipp, C. A., Wesley, R., and Rosenberg, S. A. Patterns of recurrence in patients with high grade soft tissue sarcomas, J. Clin. Oncol., 3: 353-356, 1985.
3. Elias, A. D , and Antman, K. H. Adjuvant chemotherapy of soft tissue sarcoma: an approach in search of an effective regimen. Semin. Oncol., 16: 305-311, 1989.
4. Rosenberg, S. A., Lotze, M. T., Munl, L. M., Leitman S., Change, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, E., and Vetto, J. T. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 313: 1485-1492, 1985.
5. Rosenberg, S. A., Lotze, M. T., and Mule, J. J. New approaches to the immunotherapy of cancer using interleukin-2. Ann. Intern. Med., 108: 853-864, 1988.
6. Whittington, R., and Faulds, D Interleukin-2 A review of its pharmacologic properties and therapeutic use in patients with cancer. Drugs, 46: 446-514, 1993.
7. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. Lymphokine-activated killer phenomenon. J Exp. Med., 155: 1823-1841, 1982.
8. Grimm, E A., and Owen-Schaub, L. The IL-2 mediated amplification of cellular cytoxicity, J. Cell Biochem., 45: 335-339, 1991
9. Kundig, T. M., Schorie, H., Bachman, M. F., Hengartner, H., Zinkernagel, R. M., and Horak, I. Immune responses in interleukin-2 deficient mice. Science (Washington DC), 262: 1059-1061, 1993.
10. Andreesen, R., Scheilbenbogen, C., Bragger, W., Krause, S., Meerpohl, H-G., Leser, H-G., Engler, H., and Lohr, G. W. Adopuve transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res., 50: 7450-7456, 1990.
11. Malkovsky, M., Loveland, B., North, M., Asherson, G. L., Gao, L., Ward, P., and Fiers, W. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature (Lond.), 325: 262-265, 1987.
12. Higashi, N., Nishimura, Y., Higuchi, M., and Osawa, T. Human monocytes in a long-term culture with interleuktn-2 show high tumoricidal activity against various tumor cells. J Immunol., 10: 247-255, 1991.
13. Sznol, M., Dutcher, J. P., Atkins, M. B., Rayner, A. R. A., Margolin, K. A., Gaynor, E. R., Weiss, G. R., Aronson, F., Parkinson, D R., and Hawkins, M. J. Review of interleukin-2 alone and interleukin-2/ LAK clinical trials in metastatic malignant melanoma. Cancer Treat. Rev. 15: 29-38, 1989.
14. Lotze, M. T., Chang, A. E., Seipp, C. A., Simpson, C., Vetto J. T., and Rosenberg, S. A. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer JAMA. 256: 3117-3124, 1986.
15. Mule, J. J., Shu, S., Schwartz, S. L., and Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (Washington DC), 225: 1487-1489, 1984.
16. Sleijfer, D. T., Janssen, R. A. J., Buter, J., deVries, E. G. E., Willemse, P. H. B., and Mulder, N. H. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol. 10: 1119-1123, 1992.
17. Eberlein, T. J., and Schoof, D. D. The role of interleukin-2 in cancer immunotherapy. Compr. Ther., 17: 49-56, 1991.
18. Smith, K. Lowest dose interleukin-2 immunotherapy. Blood, 81: 1414-1423, 1993.
19. Kintzel, P. E., and Calis, K. A. Recombinant interleukin-2: a biological response modifier. Clin. Pharmacol., 10: 110-128, 1991.
20. Siegal, J., and Puri, R. Interleukin toxicity. J. Clin. Oncol., 9: 694-704, 1991.
21. Peace, D. J., and Cheever, M. A. Toxicity and therapeutic efficacy of high-dose interleukin-2. J. Exp. Med., 169: 161-173, 1989.
22. Edwards, M. J., Fredrick, N. M., Sims, D. E., Abney, D. L., Schuscke, D. A., and Corey, T. S. IL-2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage. Cancer Res, 52: 3425-3431, 1992.
23. Edwards, J. E., Abney, D. L., Heniford, T., and Miller, F. N. Passive immunization against tumor necrosis factor inhibits IL-2 induced microvascular alterations and reduces toxicity. Surgery, 112: 480-486, 1992.
24. Klausner, J. M., Morel, N., Paterson, I. S., Kobzik, L., Valeri, C. R., Eberlein, T. J., Shepro, D., and Hechtman, H. B. The rapid induction by interleukin-2 of pulmonary microvascular permeability. Ann. Surg., 209: 119-128, 1989.
25. Anderson, T. D., and Hayes, T. J. Toxicity of human recombinant interleukin-2 in rats. Lab. Invest., 60: 331-346, 1989.
26. Anderson, P. M., and Sorenson, M. A. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet., 27: 19-31, 1994.
27. Caligun, M. A., Murray, C., Soiffer, R. J., Klumpp, T. R., Selden, M., Cochrane, K., Camerson, C., Ish, C., Buchanan L., Periilo, D., Smith K. A., and Ritz, J. Extended continuous infusion low dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J. Clin. Oncol., 9: 2110-2119, 1991.
28. Anderson, P. M., Hasz, D., Dickerell, L., and Sencer, S. Interleukin-2 in liposomes: increased intravenous potency and less pulmonary toxicity in the rat. Drug Dev. Res., 27: 15-31, 1992.
29. Newman, S. P., and Clarke, S. W., Therapeutic aerosols: practical considerations. Thorax, 33: 881-886, 1983.
30. Le Conte, P., Potel, G., Peltier, D., Horeau, D., Caillon, J., Juvi, M-E., Kergueris, M. F., Bugnow, D., and Baron, D. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am. Rev. Respir. Dis., 147: 1279-1282, 1993.
31. Baskin, M. I., Abd, A. G., and Ilowite, J. S. Regional deposition of aerosolized pentamidine. Ann. Intern. Med., 113: 677-683, 1990.
32. Debs, R. J., Fuchs, H. J., Philip, R., Montgomery, B., Brunette, E. N., Liggit, D., Patton, J. S., and Shellito, J. E. Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats. J. Immunol., 140: 3482-3488, 1988.
33. Maasilta, P., Halme, M., Mattson, K., and Cantell, K. Re: "Pharmacokinetics of inhaled recombinant and natural α interferon" (Letter). Lancet, 337: 371, 1991.
34. Knight, V., and Waldrep, J. C., New approaches in aerosol drug delivery for the treatment of asthma. In: B. Kay (Ed.), Allergy and Allergic Disease, Chap. 41, London: Blackwell Scientific, 1995.
35. Huland, E., Huland, H., and Heinzer, H. Interleukin-2 by inhalation: local therapy for metastatic renal carcinoma. J. Urol., 147: 344-348, 1992.
36. Zhang, Y. H., and Liu, X. Y. Inhibition of lung metastases of mouse mammary tumor by aerosolized interieukin-2 in Bacillus Calmette-Guérin primed mice. Proc. Am. Assoc. Cancer Res., 35: 519, 1994.
37. Huland, E., Heinzer, H , and Huland, H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J. Cancer Res. Clin. Oncol., 120: 221-228, 1994.
38. Anderson, P. M., Schow, D , and Leonard, A. S. Liposomal interleukin-2 synthesis and biologic activity. J. Cell Biochem. 12B(Suppl.): 255 (W100), 1988.
39. Anderson, P. M., Katsanis, E., Sencer, S. F., Hasz, D., Ochoa, A. C., and Bostrom, B. Depot characteristics and biodistribution of IL-2 liposomes: importance of route. J. Immunother., 12: 19-31, 1993.
40. Anderson, P. M., Katsanis, E., Leonard, A. S., Schow, D., Loeffler, C. M., Goldstein, M. B., and Ochoa, A. C. Increased local antitumor effects on interleukin-2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res., 50: 1853-1856, 1990.
41. Kadar, E., Rutkowski, Y., Brown, E., Emmanuel N., and Barenholz, Y. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J. Immunother. Tumor Immunol., 16: 47-59, 1994.
42. Hawkins, E. C., DeNicola, D. B., and Kuehn, N. F. Bronchoalveolar lavage in the evaluation of pulmonary disease in the dog and cat J. Vet. Intern. Med., 4: 267-274, 1990.
43. + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity. Blood, 80: 1846-1853, 1992.
44. Wee, S. L., Wu, S., Alter, B. J., and Bach, F. H. Early detection and specificity analysis of human cytolytic T lymphocytes (CTL) colonies generated in soft agarose culture: a potential assay for definition of CTL defined (CD) determinants. Hum. Immunol., 3: 45-56, 1981.
45. Espinoza-Delgadro, I., Bosca, M. C., Musso, T., Gusella, X., Longo, D. L., and Varesio, L. Interleukin-2 and human monocyte activation. J. Leukocyte Biol , 57: 13-19, 1995.
46. Gong, J. H., Maki, G., and Klingemann, H. G. Characterization of human cell line (NK92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia, 8: 652-658, 1994.
47. Russell, S. W., Pace, J. L., and Varesio, L. Comparison of five short term assays that measure nonspecific cytotoxicity mediated to tumor cells by activated macrophages. J. Leukocyte Biol., 40: 801-813, 1986.
48. De Weger, R. A., Runhaar, B. A., and Otter, W. D. Cytotoxicity by macrophages and monocytes. Methods Enzymol., 132: 458-467, 1986.
49. Campbell, M. W., Sholley, M. M., and Miller, G. A. Macrophage heterogeneity in tumor resistance: cytostatic and cytotoxic activity of Corynebacterium parvum-activated and proteose peptone-elicited rat macrophages against Moloney sarcoma tumor cells. Cell Immunol., 50: 153-168, 1980.
50. Moore, P. F., Rossitto, P. V., Danilenko, D. M., Wielenga, J., Raff, R. F., and Severns, E. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils. Tissue Antigens, 40: 75-85, 1992.
51. Danilenko, D. M., Moore, P. F., and Rossitto, P. V. Canine leukocyte cell adhesion molecules (LeuCAMs): characterization of the CD11/ CD18 family. Tissue Antigens, 40: 13-21, 1992.
52. Whitehead, R. P., Ward, P., Hemingway, L., Harstreet, G. P., Bradley, E., and Konrad, M. Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res., 50: 6708-6715, 1990.
53. Gillis, S., Ferm, M. M., Ou, W., and Smith, K. A. T cell growth factor: parameters of production and quantitative microassay for activity. J. Immunol., 120: 2027-2032, 1978.
54. Khanna, C., Anderson, P. M., Hasz, D., and Klausner, J S. Aerosol delivery of interleukin-2 liposomes is non-toxic and effective: murine and canine studies. Proc. Am. Assoc. Cancer Res., 35: 414, 1994.
55. Flexman, J. P., Manning, L. S., and Robinson, B. W. S. In vivo boosting of lung natural killer and lymphokine activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes. Clin. Exp. Immunol., 82: 151-156, 1990.
56. Withrow, S. J., Powers, B. E., Straw, R. C., and Wilkins, R. M. Comparative aspects of osteosarcoma. Clin. Orthop., 270: 159-168, 1989.
57. Hahn, K. J., Bravo, L., Adams, W. H., and Frazier, D. L. Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo (Athens). 8: 133-144, 1994.
58. Ogilvie, G. K., Straw, R. C., and Jameson, V. J. Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991). J. Am. Vet. Med. Assoc., 202: 304-306, 1993.
59. Huland, E., and Huland, H. Local continuous high dose interleukin-2: a new therapeutic model for the treatment of advanced bladder cancer. Cancer Res., 49: 5469-5474, 1989.
60. Yasumoto, K., Miyazaki, M., Nagashima, A., Ishida, T., Kuda T., Yano, T , Sugimachi, K., and Nomoto, K. Introduction of lymphokine activated killer cells by intrapleural instillation of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res., 47: 2184-2187, 1987.
61. Eggermont, A. A. M., Goey, S. H., Slingerland, R., Jansen, R. L. H., Oosterom, R., Bolhuis, R. L. H., and Stuter, G. Clinical and immunologic evaluation of intrapleural iriterleukin-2 in malignant pleural mesothelioma: a phase I-II study. Proc. Am. Assoc. Cancer Res., 32: 206, 1991.
62. Blanchard, D. K., Kavanagh, J. J., Sinkovics, J. G , Cavanagh, D., Hewitt, S. M., and Djeu, J. Y Infiltration of interleukin-2 inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients. Cancer Res., 48: 6321-6327, 1988.
63. Yasumoto, K., and Ogura, T. Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Biotherapy, 3: 345-349, 1991.
64. Ostro, M. J. Liposomes. Sci. Am., 257: 102-107, 1987.
65. Ostro, M. J., and Peiter, R. C. Use of liposomes as injectable-drug delivery systems. Am. J. Hosp. Pharm., 46: 1576-1587, 1989.
66. Anderson, P. M., Hanson, D. H., Hasz, D., Halet, M. R., Blazer, B. R., and Ochoa, A. C. Cytokines in liposomes: depot preparations of IL-1, IL-2, IL-6, GM-CSF, and γ interferon. Cytokine, 6: 92-101, 1994.
67. Gause, B., Longo, D. L., Janik, J., Smith, I. I., Curti, B , Ochoa, A., Kopp, W. C., Anderson, P. M., and Urba, N. J. A phase I study of liposome encapsulated IL-2 (LE-IL-2). Proc. Am. Soc. Clin. Oncol., 12: 955, 1993.
68. Taylor, K. M. G., Taylor, G., Kellaway, I. W., and Stevens, J. The stability of liposomes to nebulisation Int J. Pharm. (Amst.), 58: 57-61, 1990.
69. Niven, R. W., and Schreier, H. Nebulization of liposomes. I. Effects of lipid composition. Pharm, Res. (NY), 7: 1127-33, 1990.
70. Niven, R. W., Speir, M., and Schreier, H. Nebulization of Liposomes. II Effects of size and modeling of solute release profiles. Pharm. Res. (NY),8: 217-221, 1991
71. Niven, R. W., Carvajal, T. M., and Schreier, H. Nebulization of liposomes. III. Effects of operating conditions and local environment. Pharm. Res. (NY), 9: 515-520, 1992.
72. Alvine, G., Rodfers, P., Fitzsimmons, K., and Ahrens, R. Disposable jet nebulizers. Chest, 101: 316-319, 1992.
73. Malone, R. A., Hollie, M. C., Glynn-Barnhart, A., and Nelson, H. S. Optimal duration of nebulized albuterol therapy. Chest, 104, 114-118, 1993.
74. Thomas, S. H. L., O'Doherty, M. J., Page, C. J., Treacher, D. J., and Nunan, T O Delivery of ultrasonic nebulized aerosols to a lung model. Am. Rev. Respir. Dis., 148: 872-877, 1993.
75. Waldrep, J. C., Scherer, P. W., Hess, G. H , Black, M., and Knight, V. Nebulized glucocorucoids in liposomes: aerosol characteristics and human dose estimates. J. Aerosol Med., 7: 135-145, 1994.
76. Waldrep, J. C., Keyhani, K., Black, M., and Knight, V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest, 105: 106-110, 1994.
77. Knight, V., Black, M. T., and Waldrep, J. C. Development of cyclosporin-A liposome aerosol therapy for pulmonary diseases. Proc. Am. Thoracic Soc./Am. Lung Assoc., No. 299718, 1994
78. Vidgren, M., Waldrep, J. C., Black, M. T., Arppe, J., and Knight, V. Radiolabelling of beclomethasone dipropionate-liposome formulation for aerosol deposition studies. Proc. Am. Thoracic Soc./Am. Lung Assoc., No. 131582, 1994.
79. Waldrep, J. C., Scherer, P. W., Keyhani, K., and Knight, V. Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition. Int. J. Pharm. (Amst.), 87: 205-212, 1993.
80. Gilbert, B. E., Wilson, S. Z., Garcon, N. M., Wyde, P. R., and Knight, P. R. Characterization and administration of cyclosporine liposomes as a small particle aerosol. Transplantation. 56: 974-977, 1993.
81. Alexander, A. G., Barnes, N. C., and Kay, A. B. Trial of cyclosporin in cordcosteroid-dependent chronic severe asthma. Lancet, 339: 324-328, 1992.
82. Helfand, S. C., Soergel, S. A., MacWilliams, P. S., Hank, J. A., and Sondel, P. M, Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs. Cancer Immunol. Immunother., 39: 84-92, 1994.
83. Da Pozzo, L. F., Hough, K. L., and Holder, W. D. Toxicity and immunologic effects of continuous infusion of recombinant interleukin-2 administered by selective hepatic perfusion in dogs. Surgery, 111: 326-334, 1992.
84. Harmsen, A. G., Muggenburg, B. A., Snipes, M. B., and Bice, D. E. The role of macrophages in particle translocation from lungs to lymph nodes. Science (Washington DC), 230: 1277-1280, 1985
85. Kobzik, L., Huang, S., Paulauskis, J D., and Godleski, J. J. Particle opsonization and lung macrophage cytokine response. J. Immunol., 151: 2753-2759, 1993.
86. Bienenstock, J. The lung as an immunologic organ. Annu. Rev. Med., 35: 49-62, 1984.
87. Lohmann-Matthes, M L., Emmendoerffer, A., and Hao, L. Influence of interleukin-2 on the differentiation of macrophages. Pathobiology, 59: 117-121, 1991.
88. Sobach, W., Moll, H., and Rollinghoff, M. Lymphocytes play the music but the macrophage calls the tune. Immunol Today, 12: 4-6, 1991.
89. Gusella, G L., Musso, T., Bosco, M. C., Espinoza-Delado, I., Matsushima, K., and Varesio, L. IL-2 up-regulates but IFN-γ suppresses IL-8 expression in human monocytes. J. Immunol., 151: 2725-2732, 1993.
90. Duerksen-Hughes, P. J., and Gooding, L. R. Macrophage-mediated cytotoxicity. In: M. Sitkovsky and P. Henkart (Eds.), Cytotoxic Cells. Boston. Birkhauser Boston, 439-454, 1993.
91. Helfand, S. C., Modiano, J. F., and Nowell, P. C. Immunophysical studies of interleukin-2 and canine lymphocytes Vet. Immunol. Immunopathol., 33: 1-16, 1992.
92. Somberg, R. L., Robinson, J. P, and Felsberg, P. J. Detection of canine interleukin-2 receptors by flow cytometry. Vet. Immunol. Immunopathol., 33: 17-24, 1992.
93. Mitchell, D. H., Withrow, S. J., Johnston, M. R., and Kruse, C. A. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant mterleukin-2 activated lymphocytes from healthy dogs and dogs with lung tumors. Am. J. Vet. Res., 52: 1132-1136, 1991